AAPL338.64+2.51 (+0.75%) ▲|ABBV264.89+0.93 (+0.35%) ▲|ABT102.79+0.18 (+0.18%) ▲|ACN186.50+5.21 (+2.87%) ▲|ADBE248.48-0.45 (-0.18%) ▼|AMAT463.02+18.45 (+4.15%) ▲|AMD607.54+47.72 (+8.52%) ▲|AMGN392.25+6.60 (+1.71%) ▲|AMT174.92+0.94 (+0.54%) ▲|AMZN258.87+5.16 (+2.03%) ▲|AVGO360.15+3.19 (+0.89%) ▲|AXP313.31+1.75 (+0.56%) ▲|BA200.47+2.27 (+1.15%) ▲|BAC58.06+0.33 (+0.56%) ▲|BKNG169.06+1.16 (+0.69%) ▲|BLK1,081.03+11.25 (+1.05%) ▲|BMY62.98-0.09 (-0.13%) ▼|BNY153.75-0.05 (-0.03%) ▼|BRK-B506.56-3.21 (-0.63%) ▼|C135.11+3.34 (+2.53%) ▲|CAT818.32+9.33 (+1.15%) ▲|CL86.20-1.28 (-1.46%) ▼|CMCSA22.99+0.25 (+1.08%) ▲|COF205.08+2.65 (+1.31%) ▲|COP127.91-3.92 (-2.97%) ▼|COST896.37+1.06 (+0.12%) ▲|CRM237.77-0.15 (-0.06%) ▼|CSCO109.70+0.19 (+0.17%) ▲|CVS87.41-1.43 (-1.61%) ▼|CVX204.65-4.86 (-2.32%) ▼|DE692.05+8.06 (+1.18%) ▲|DHR214.00+2.19 (+1.03%) ▲|DIS104.24+1.57 (+1.52%) ▲|DUK117.29-0.24 (-0.20%) ▼|EMR151.54+1.62 (+1.08%) ▲|FDX292.60-11.05 (-3.64%) ▼|GD353.96+0.91 (+0.26%) ▲|GE320.30+6.03 (+1.92%) ▲|GEV953.76+13.43 (+1.43%) ▲|GILD151.35+1.24 (+0.82%) ▲|GM84.73+2.53 (+3.07%) ▲|GOOG352.56+8.15 (+2.37%) ▲|GOOGL356.48+6.94 (+1.98%) ▲|GS954.43+12.43 (+1.32%) ▲|HD298.17-1.82 (-0.61%) ▼|HON206.03-0.43 (-0.21%) ▼|IBM228.67-0.88 (-0.38%) ▼|INTC121.77+13.17 (+12.13%) ▲|INTU303.06-0.14 (-0.04%) ▼|ISRG399.43+6.10 (+1.55%) ▲|JNJ271.03+1.04 (+0.39%) ▲|JPM351.94+2.27 (+0.65%) ▲|KO87.73-0.53 (-0.59%) ▼|LIN457.46-2.94 (-0.64%) ▼|LLY1,165.90+12.97 (+1.12%) ▲|LMT533.85+0.47 (+0.09%) ▲|LOW191.74-0.75 (-0.39%) ▼|LRCX301.79+13.68 (+4.75%) ▲|MA565.12-0.12 (-0.02%) ▼|MCD247.75-0.49 (-0.20%) ▼|MDLZ60.33-0.53 (-0.86%) ▼|MDT91.87-0.26 (-0.28%) ▼|META742.62+77.40 (+11.63%) ▲|MMM165.45-0.45 (-0.27%) ▼|MO68.75-0.78 (-1.11%) ▼|MRK149.39+2.52 (+1.71%) ▲|MS205.66+3.08 (+1.52%) ▲|MSFT498.35+4.57 (+0.92%) ▲|MU1,039.75+23.95 (+2.36%) ▲|NEE79.86-0.61 (-0.76%) ▼|NFLX73.35+1.56 (+2.17%) ▲|NKE36.01+0.50 (+1.41%) ▲|NOW137.30+1.83 (+1.35%) ▲|NVDA227.38+5.11 (+2.30%) ▲|ORCL148.94+1.33 (+0.90%) ▲|PEP129.75+0.00 (+0.00%) ▲|PFE27.73+0.07 (+0.25%) ▲|PG146.51+0.12 (+0.08%) ▲|PLTR181.82+4.18 (+2.35%) ▲|PM187.97-0.65 (-0.34%) ▼|QCOM192.25+14.53 (+8.17%) ▲|RTX194.47+0.47 (+0.24%) ▲|SBUX94.54-1.30 (-1.35%) ▼|SCHW106.97+1.72 (+1.63%) ▲|SO85.78+0.26 (+0.30%) ▲|SPG204.91-0.41 (-0.20%) ▼|T25.65+0.25 (+0.99%) ▲|TMO657.21+5.76 (+0.88%) ▲|TMUS167.09-1.10 (-0.65%) ▼|TSLA374.29+10.02 (+2.75%) ▲|TXN269.02+2.38 (+0.89%) ▲|UBER71.06+0.56 (+0.79%) ▲|UNH376.99+0.09 (+0.02%) ▲|UNP270.44-8.93 (-3.20%) ▼|UPS94.27-4.79 (-4.84%) ▼|USB60.38+0.32 (+0.52%) ▲|V368.04-0.25 (-0.07%) ▼|VZ47.82-0.28 (-0.57%) ▼|WFC86.54+0.42 (+0.49%) ▲|WMT107.45+0.72 (+0.67%) ▲|XOM158.84-4.70 (-2.87%) ▼|AAPL338.64+2.51 (+0.75%) ▲|ABBV264.89+0.93 (+0.35%) ▲|ABT102.79+0.18 (+0.18%) ▲|ACN186.50+5.21 (+2.87%) ▲|ADBE248.48-0.45 (-0.18%) ▼|AMAT463.02+18.45 (+4.15%) ▲|AMD607.54+47.72 (+8.52%) ▲|AMGN392.25+6.60 (+1.71%) ▲|AMT174.92+0.94 (+0.54%) ▲|AMZN258.87+5.16 (+2.03%) ▲|AVGO360.15+3.19 (+0.89%) ▲|AXP313.31+1.75 (+0.56%) ▲|BA200.47+2.27 (+1.15%) ▲|BAC58.06+0.33 (+0.56%) ▲|BKNG169.06+1.16 (+0.69%) ▲|BLK1,081.03+11.25 (+1.05%) ▲|BMY62.98-0.09 (-0.13%) ▼|BNY153.75-0.05 (-0.03%) ▼|BRK-B506.56-3.21 (-0.63%) ▼|C135.11+3.34 (+2.53%) ▲|CAT818.32+9.33 (+1.15%) ▲|CL86.20-1.28 (-1.46%) ▼|CMCSA22.99+0.25 (+1.08%) ▲|COF205.08+2.65 (+1.31%) ▲|COP127.91-3.92 (-2.97%) ▼|COST896.37+1.06 (+0.12%) ▲|CRM237.77-0.15 (-0.06%) ▼|CSCO109.70+0.19 (+0.17%) ▲|CVS87.41-1.43 (-1.61%) ▼|CVX204.65-4.86 (-2.32%) ▼|DE692.05+8.06 (+1.18%) ▲|DHR214.00+2.19 (+1.03%) ▲|DIS104.24+1.57 (+1.52%) ▲|DUK117.29-0.24 (-0.20%) ▼|EMR151.54+1.62 (+1.08%) ▲|FDX292.60-11.05 (-3.64%) ▼|GD353.96+0.91 (+0.26%) ▲|GE320.30+6.03 (+1.92%) ▲|GEV953.76+13.43 (+1.43%) ▲|GILD151.35+1.24 (+0.82%) ▲|GM84.73+2.53 (+3.07%) ▲|GOOG352.56+8.15 (+2.37%) ▲|GOOGL356.48+6.94 (+1.98%) ▲|GS954.43+12.43 (+1.32%) ▲|HD298.17-1.82 (-0.61%) ▼|HON206.03-0.43 (-0.21%) ▼|IBM228.67-0.88 (-0.38%) ▼|INTC121.77+13.17 (+12.13%) ▲|INTU303.06-0.14 (-0.04%) ▼|ISRG399.43+6.10 (+1.55%) ▲|JNJ271.03+1.04 (+0.39%) ▲|JPM351.94+2.27 (+0.65%) ▲|KO87.73-0.53 (-0.59%) ▼|LIN457.46-2.94 (-0.64%) ▼|LLY1,165.90+12.97 (+1.12%) ▲|LMT533.85+0.47 (+0.09%) ▲|LOW191.74-0.75 (-0.39%) ▼|LRCX301.79+13.68 (+4.75%) ▲|MA565.12-0.12 (-0.02%) ▼|MCD247.75-0.49 (-0.20%) ▼|MDLZ60.33-0.53 (-0.86%) ▼|MDT91.87-0.26 (-0.28%) ▼|META742.62+77.40 (+11.63%) ▲|MMM165.45-0.45 (-0.27%) ▼|MO68.75-0.78 (-1.11%) ▼|MRK149.39+2.52 (+1.71%) ▲|MS205.66+3.08 (+1.52%) ▲|MSFT498.35+4.57 (+0.92%) ▲|MU1,039.75+23.95 (+2.36%) ▲|NEE79.86-0.61 (-0.76%) ▼|NFLX73.35+1.56 (+2.17%) ▲|NKE36.01+0.50 (+1.41%) ▲|NOW137.30+1.83 (+1.35%) ▲|NVDA227.38+5.11 (+2.30%) ▲|ORCL148.94+1.33 (+0.90%) ▲|PEP129.75+0.00 (+0.00%) ▲|PFE27.73+0.07 (+0.25%) ▲|PG146.51+0.12 (+0.08%) ▲|PLTR181.82+4.18 (+2.35%) ▲|PM187.97-0.65 (-0.34%) ▼|QCOM192.25+14.53 (+8.17%) ▲|RTX194.47+0.47 (+0.24%) ▲|SBUX94.54-1.30 (-1.35%) ▼|SCHW106.97+1.72 (+1.63%) ▲|SO85.78+0.26 (+0.30%) ▲|SPG204.91-0.41 (-0.20%) ▼|T25.65+0.25 (+0.99%) ▲|TMO657.21+5.76 (+0.88%) ▲|TMUS167.09-1.10 (-0.65%) ▼|TSLA374.29+10.02 (+2.75%) ▲|TXN269.02+2.38 (+0.89%) ▲|UBER71.06+0.56 (+0.79%) ▲|UNH376.99+0.09 (+0.02%) ▲|UNP270.44-8.93 (-3.20%) ▼|UPS94.27-4.79 (-4.84%) ▼|USB60.38+0.32 (+0.52%) ▲|V368.04-0.25 (-0.07%) ▼|VZ47.82-0.28 (-0.57%) ▼|WFC86.54+0.42 (+0.49%) ▲|WMT107.45+0.72 (+0.67%) ▲|XOM158.84-4.70 (-2.87%) ▼|
22.3 C
New York
Monday, September 21, 2026

Tag: securities

newssourceFORcompanyinformationcontent1releasesmarket

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Atai Life Sciences N.V. (NASDAQ: ATAI)

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Atai Life Sciences N.V. (NASDAQ: ATAI) related to the acquisition of Beckley Psytech Limited. Is it a fair deal?

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline.

CAR 截止日期提醒：廣受信賴的投資人法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Avis Budget Group, Inc 投資人於 6 月 24 日證券集體訴訟重要截止日期前聘請律師 – CAR

紐約, June 15, 2025 (GLOBE NEWSWIRE) --

事由：全球投資人權益律師事務所 Rosen Law Firm 提醒在 2024 年 2 月 16 日至 2025 年 2 月 10 日（含首尾兩天，簡稱「集體訴訟期間」）期間購買 Avis Budget Group, Inc. (NASDAQ: CAR) 股票的人士，2025 年 6 月 24 日是重要的首席原告截止日期。

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe jamais présentée

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action 
NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action

IBTA 最終截止日期：享譽全球的律師事務所 ROSEN 鼓勵損失超過 10 萬美元的 Ibotta, Inc. 投資者在該事務所對 IBTA 首次提出證券集體訴訟之重要截止日期 6 月 16 日前聘請律師

紐約, June 15, 2025 (GLOBE NEWSWIRE) --

事因：全球投資者權益律師事務所 Rosen Law Firm 提醒：(1) 根據及／或可追溯至因 Ibotta, Inc.（NYSE: IBTA）於 2024 年 4 月 18 日進行首次公開招股（簡稱「IPO」）所發行之註冊聲明及相關招股章程（統稱「註冊聲明」）而購買該公司證券之人士；或 (2) 於 2024 年 4 月 18 日至 2025 年 2 月 26 日期間（包括首尾兩日，簡稱「集體訴訟期」）購買該公司證券之人士注意，該事務所首次提出證券集體訴訟之重要首席原告截止日期為 2025 年 6 月 16 日。

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoubleVerify

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DoubleVerify To Contact Him Directly To...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSecurities

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers